Compare CVNA & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | RMD |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 36.4B |
| IPO Year | 2017 | 1995 |
| Metric | CVNA | RMD |
|---|---|---|
| Price | $402.54 | $271.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 11 |
| Target Price | ★ $449.74 | $293.70 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 02-18-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.90% |
| EPS Growth | N/A | ★ 19.37 |
| EPS | 4.40 | ★ 10.11 |
| Revenue | ★ $18,266,000,000.00 | $5,398,119,000.00 |
| Revenue This Year | $49.04 | $9.88 |
| Revenue Next Year | $27.64 | $7.37 |
| P/E Ratio | $87.28 | ★ $26.41 |
| Revenue Growth | ★ 45.55 | 9.57 |
| 52 Week Low | $148.25 | $199.92 |
| 52 Week High | $486.89 | $293.81 |
| Indicator | CVNA | RMD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.33 |
| Support Level | N/A | $250.54 |
| Resistance Level | N/A | $258.45 |
| Average True Range (ATR) | 0.00 | 6.84 |
| MACD | 0.00 | 1.12 |
| Stochastic Oscillator | 0.00 | 99.63 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.